Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Completed · Phase 2

Conditions studied: Osteoarthritis of the Shoulder, Osteoarthritis of the Hip

In brief

This is an open-label study to compare systemic exposure to triamcinolone acetonide following a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip

Key facts

Study ID

NCT03382262

Run by

Pacira Pharmaceuticals, Inc

People needed

55

Starts

2017-12-18

Expected to finish

2018-10-09

Last updated by the study team

2024-01-24

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written consent to participate in the study
• Male or female greater than or equal to 40 years of age
• Body mass index (BMI) less than or equal to 40 kg/m2
• Ambulatory and in good general health
• Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
• Willing to abstain from use of protocol-restricted treatments from Screening through End-of-Study visit
• Symptoms consistent with OA of the index joint for ≥ 6 months prior to Screening (patient reported is acceptable)
• Pain in the index joint for greater than15 days over the last month (as reported by the patient)
• For Shoulder OA patients: Radiologic findings of OA of the index shoulder meeting the Samilson-Prieto (S-P) Classification Grades 2 or 3
• For Hip OA patients: ACR Criteria (clinical and radiological) for OA of the index hip

You may not qualify if…

• Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
• History of infection in the index joint
• Clinical findings consistent with active infection or crystal disease in the index joint within 1 month of Screening
• History of fracture in the index limb within 12 months of Screening, or fracture with sequelae at any time
• Planned or anticipated surgery of the index joint during the study period
• Index joint instability or history of acute dislocation within 12 months of Screening
• If shoulder is the index joint, history of full or partial rotator cuff tear or significantly compromised rotator cuff function that, in the opinion for the Investigator, increases the difficulty or risk of IA injection
• Presence of surgical hardware or other foreign body in the index joint
• Surgery or arthroscopy of the index joint within 12 months of Screening
• IA treatment of any joint with any of the following agents within 6 months of Screening:
• Any corticosteroid preparation (investigational or marketed, including FX006), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed)
• IA treatment of the index joint with hyaluronic acid (investigational or marketed) within 6 months of Screening
• Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
• Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
• Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study

Where it is running

• TriWest Research Associates, LLC — El Cajon, California, United States
• Biosolutions Clinical Research Center — La Mesa, California, United States
• Artemis Institute for Clinical Research — San Diego, California, United States
• LA Biomed at Harbor-UCLA Medical Center — Torrance, California, United States
• Rochester Clinical Research — Rochester, New York, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.